Skip to main content
Clinical Trials/NCT03853161
NCT03853161
Unknown
Not Applicable

A Multicenter Randomized Controlled Trial Comparing High Flow Nasal Cannula and NIPPV in Preterm Infants

Carmel Medical Center1 site in 1 country130 target enrollmentJanuary 21, 2018
ConditionsPreterm Infant

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Preterm Infant
Sponsor
Carmel Medical Center
Enrollment
130
Locations
1
Primary Endpoint
Rate of intubation within 7 days of starting the study treatment
Last Updated
5 years ago

Overview

Brief Summary

The aim of this study is to compare the effectiveness of Heated Humidified High Flow Nasal Cannula (HHHFNC) versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) in preventing intubation when used as primary respiratory support for Respiratory Distress Syndrome (RDS) or post extubation in preterm infants

Detailed Description

Patient population will include preterm infants born at 24 - 36+6 weeks of gestation who are candidates for non-invasive respiratory support post extubation or as primary respiratory support after birth. They will be will be randomized to 2 groups: Heated Humidified High Flow Nasal Cannula (HHHFNC) and Nasal Intermittent Positive Pressure Ventilation (NIPPV). This will be a prospective unblinded randomized controlled study, designed as a non-inferiority trial. Primary outcome: The primary outcome will be rate of treatment failure (need for intubation) within 7 days of starting the study treatment

Registry
clinicaltrials.gov
Start Date
January 21, 2018
End Date
July 1, 2023
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Carmel Medical Center
Responsible Party
Principal Investigator
Principal Investigator

Ayala Gover

principal investigator

Carmel Medical Center

Eligibility Criteria

Inclusion Criteria

  • Infants born at 24-27+6 weeks of gestation and up to 28 days of life who are extubated for the first time after birth or immediately after surfactant administration via (intubation-surfactant-extubation) INSURE or (minimally invasive surfactant therapy) MIST procedures.
  • Infants born at 28-36+6 weeks of gestation and up to 28 days of life who are candidates for non-invasive support either as a primary modality after birth or post extubation.
  • Signed parental informed consent by one of the parents

Exclusion Criteria

  • Infants who are unlikely to survive the immediate postnatal period or who have significant congenital abnormalities
  • Presence of a pneumothorax prior to enrollment
  • Hemodynamic instability due to sepsis or hemorrhage
  • Inability to obtain parental consent
  • Shortage of suitable equipment
  • Infants who were intubated solely for surgery

Outcomes

Primary Outcomes

Rate of intubation within 7 days of starting the study treatment

Time Frame: one week

Failure of non invasive support by criteria of pH, blood carbon dioxide level, oxygen requirements or apneas

Study Sites (1)

Loading locations...

Similar Trials